Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Net Loans Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Preferred Shares Issued Preferred Shares Repurchased Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Fortress Biotech (FBIO) Gains from Investment Securities (2016 - 2025)

Fortress Biotech has reported Gains from Investment Securities over the past 12 years, most recently at $540000.0 for Q3 2025.

Quarterly results put Gains from Investment Securities at $540000.0 for Q3 2025, changed 0.0% from a year ago — trailing twelve months through Dec 2025 was -$572000.0 (down 80.44% YoY), and the annual figure for FY2025 was $8.4 million, up 300.0%.
Gains from Investment Securities for Q3 2025 was $540000.0 at Fortress Biotech, roughly flat from $540000.0 in the prior quarter.
Over the last five years, Gains from Investment Securities for FBIO hit a ceiling of $540000.0 in Q2 2024 and a floor of -$661000.0 in Q4 2021.
Median Gains from Investment Securities over the past 5 years was $2500.0 (2022), compared with a mean of $105568.6.
Biggest five-year swings in Gains from Investment Securities: tumbled 267.84% in 2023 and later surged 325201.2% in 2024.
Fortress Biotech's Gains from Investment Securities stood at -$661000.0 in 2021, then surged by 138.58% to $255000.0 in 2022, then tumbled by 267.84% to -$428000.0 in 2023, then skyrocketed by 66.36% to -$144000.0 in 2024, then surged by 475.0% to $540000.0 in 2025.
The last three reported values for Gains from Investment Securities were $540000.0 (Q3 2025), $540000.0 (Q2 2025), and $540000.0 (Q1 2025) per Business Quant data.